<DOC>
	<DOCNO>NCT00464178</DOCNO>
	<brief_summary>The purpose study determine whether combination bevacizumab bortezomib increase efficacy treatment relapsed/ refractory multiple myeloma .</brief_summary>
	<brief_title>A Phase II Study Bevacizumab Bortezomib Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Rationale : With identification thalidomide active agent Multiple Myeloma , role angiogenesis pathogenesis become subject much investigation . Micro vessel density ( neovascularization ) inversely related prognosis Multiple Myeloma . Response thalidomide felt correlate decline microvessel density ( Singhal et al NEJM ) . While mechanism neovascularization yet fully elucidate , number model show VEGF play central role . Thalidomide show synergize number agent use treat MM , include bortezomib . ( Wang et al ASH 2005 ) This would justify use therapeutic know antiangiogenic activity conjunction establish antimyeloma therapy . Bortezomib , precedence know synergy Thalidomide extremely well establish optimal dose , schedule , response rate , event free survival , overall survival would make excellent candidate combination therapy establish antiangiogenic compound . There several report role VEGF multiple myeloma . It show multiple myeloma cell secreteVEGF , promote production IL-6 BMSCs , well migration proliferation tumor cell . Thus VEGF autocrine growth factor trigger IL-6-mediated paracrine multiple myeloma cell growth . Recent report highlight major role VEGF multiple myeloma pathogenesis , demonstrate VEGF also increase microvessel density bone marrow . VEGF also inhibit dendritic cell . Taken together , preclinical report make strong suggestion promise VEGF target agent multiple myeloma ( Le Gouill et al 2004 ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Myeloma Proteins</mesh_term>
	<criteria>Must previously diagnose multiple myeloma base DurieSalmon criterion and/or diagnostic criterion develop International Myeloma Working Group ( IMWG ) .The patient must currently require therapy relapse ( progressive disease , define 25 % increase Mprotein , development new worsen exist lesion soft tissue plasmacytoma , hypercalcemia , relapse CR . Or patient must disease refractory recent therapy . Defined less 50 % reduction serum paraprotein 90 % reduction urine paraprotein . Must measurable disease , define follow : For secretory multiple myeloma , measurable level monoclonal protein : great equal 0.5g/dL electrophoresis great equal 200mg monoclonal light chain 24 hour protein electrophoresis . Must least one prior line therapy three prior line therapy . Must understand voluntarily sign informed consent form . Must great than/equal 18 year age time sign consent . Must able adhere study visit schedule protocol requirement . Must ECOG performance status 0,1or 2 Women Childbearing potential ( WCBP ) define sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive method ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study medication . All WCBP sexually active male patient must agree use adequate method birth control throughout study . Inability comply study and/or followup procedure Life expectancy le 12 week Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure leave ventricular ejection fraction ( LVEF ) &lt; 40 % ( Note : baseline evaluation LVEF perform patient receive &gt; 450mg/m2 anthracycline prior chemotherapy . History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Known CNS disease Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Known hypersensitivity component bevacizumab and/or bortezomib Previously treat Bortezomib and/or Bevacizumab . Received nitrosoureas within 3 week chemotherapy , include thalidomide clarithromycin , radiation therapy enrollment . Received corticosteroid ( great 10mg/day prednisone equivalent ) within three week prior enrollment . Received immunotherapy antibody therapy within 8 week prior enrollment . Received plasmapheresis within 4 week enrollment . Had major surgery within 4 week enrollment . ( kyphoplasty consider major surgery ) History allergic reaction attributable compound contain boron mannitol . Grade 3 great peripheral neuropathy define NCI Common Toxicity Criteria ( NCI CTC version 3.0 ) Grade 3 : Sensory loss paresthesia interfere ADLs . Grade 4 : Permanent sensory loss interfere function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>myeloma</keyword>
	<keyword>relapse myeloma</keyword>
	<keyword>refractory myeloma</keyword>
	<keyword>relapse , refractory myeloma</keyword>
	<keyword>relapse , refractory multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse multiple myeloma</keyword>
	<keyword>B lymphoid malignancy</keyword>
	<keyword>Myeloma , Plasma-Cell</keyword>
	<keyword>Myeloma Proteins</keyword>
	<keyword>hnRNP A1</keyword>
	<keyword>myeloma helix-destabilizing protein , mouse</keyword>
	<keyword>IgC3kappa Jir protein , human</keyword>
	<keyword>gamma 3 myeloma protein Jir , human</keyword>
	<keyword>M-proteins ( Myeloma )</keyword>
	<keyword>M315 myeloma protein , mouse</keyword>
	<keyword>myeloma protein M 315 , mouse</keyword>
	<keyword>McPC603 antibody</keyword>
	<keyword>myeloma protein McPC603 antibody</keyword>
	<keyword>multiple myeloma M-proteins</keyword>
	<keyword>M protein , multiple myeloma</keyword>
	<keyword>myeloma cell activator</keyword>
	<keyword>myeloma immunoglobulin</keyword>
	<keyword>myeloma immunoglobulin M603</keyword>
	<keyword>myeloma immunoglobulin S15</keyword>
	<keyword>myeloma protein A48 , mouse</keyword>
	<keyword>A48 myeloma protein , mouse</keyword>
	<keyword>ABPC48 myeloma protein , mouse</keyword>
	<keyword>myeloma protein A 48 , mouse</keyword>
	<keyword>myeloma protein Dob</keyword>
	<keyword>myeloma protein M 467</keyword>
	<keyword>myeloma protein M467</keyword>
	<keyword>myeloma protein MOPC 141 , mouse</keyword>
	<keyword>MOPC141 myeloma protein , mouse</keyword>
	<keyword>myeloma protein MOPC 173</keyword>
	<keyword>myeloma protein Rou</keyword>
	<keyword>IgA2 myeloma protein Rou</keyword>
	<keyword>myeloma protein TEPC15</keyword>
	<keyword>myeloma protein T15</keyword>
	<keyword>myeloma protein TEPC 15</keyword>
	<keyword>myeloma protein W3129</keyword>
	<keyword>myeloma protein WIE</keyword>
	<keyword>myeloma-associated membrane antigen KMA</keyword>
	<keyword>myeloma antigen KMA</keyword>
	<keyword>MYEOV protein , human</keyword>
	<keyword>protein 460</keyword>
	<keyword>myeloma protein MOPC 460</keyword>
	<keyword>TRAPPC1 protein , human</keyword>
	<keyword>multiple myeloma protein 2 , human</keyword>
	<keyword>Wis heavy-chain disease protein , human</keyword>
	<keyword>myeloma protein Wis , human</keyword>
</DOC>